EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A case of anti-laminin 332-type mucous membrane pemphigoid with ocular symptoms successfully treated with mycophenolate mofetil and prednisolone in an elderly man

Shoko Fukumitsu, Takashi Hashimoto, Yukari Matsumoto, Takayuki Nagai, Keisuke Iritani, Yoshiaki Hirako, Akiharu Kubo, Takeshi Fukumoto

Journal of Cutaneous Immunology and Allergy · 11.08.2026 · 9

DOI: 10.3389/jcia.2026.16615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Immunology and Allergy, online erschienen am 11.08.2026. Verfasst von Shoko Fukumitsu und 7 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Fukumitsu, S., Hashimoto, T., Matsumoto, Y., Nagai, T., Iritani, K., Hirako, Y., Kubo, A., & Fukumoto, T. (2026). A case of anti-laminin 332-type mucous membrane pemphigoid with ocular symptoms successfully treated with mycophenolate mofetil and prednisolone in an elderly man. Journal of Cutaneous Immunology and Allergy, 9. https://doi.org/10.3389/jcia.2026.16615

Vancouver

Fukumitsu S, Hashimoto T, Matsumoto Y, Nagai T, Iritani K, Hirako Y, et al. A case of anti-laminin 332-type mucous membrane pemphigoid with ocular symptoms successfully treated with mycophenolate mofetil and prednisolone in an elderly man. Journal of Cutaneous Immunology and Allergy. 2026;9. doi:10.3389/jcia.2026.16615

BibTeX
@article{Fukumitsu2026,
  author = {Fukumitsu, Shoko and Hashimoto, Takashi and Matsumoto, Yukari and Nagai, Takayuki and Iritani, Keisuke and Hirako, Yoshiaki and Kubo, Akiharu and Fukumoto, Takeshi},
  title = {A case of anti-laminin 332-type mucous membrane pemphigoid with ocular symptoms successfully treated with mycophenolate mofetil and prednisolone in an elderly man},
  journal = {Journal of Cutaneous Immunology and Allergy},
  year = {2026},
  volume = {9},
  doi = {10.3389/jcia.2026.16615}
}
Kostenlos starten →